There are differences between familial and idiopathic pulmonary fibrosis in terms of cluster of differentiation 20 and CD3 expression.
After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
AbCellera today announced new data on its PSMA x CD3 T-cell engagers, presented as a poster at the American Association for Cancer ResearchⓇ 116th Annual Meeting at the McCormick Place Convention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results